

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

NeuroSearch announces the end of stabilisation period in connection with the rights issue, completed November 2007

With reference to announcement no. 29-07 from 27 November 2007, regarding the completion of a rights issue, NeuroSearch hereby announces that the stabilisation period expired on 28 December 2007. Carnegie Bank A/S and Danske Markets, division of Danske Bank A/S, acted as Joint Global Coordinators and stabilisation agents in connection with the rights issue.

The Joint Global Coordinators have notified the company that no stabilisation measures have been taken with regard to NeuroSearch A/S' shares within the stabilisation period.

Asger Aamund
Chairman of the Board

Contact persons:

Flemming Pedersen, CEO

Hanne Leth Hillman, Vice President,
Director of Investor Relations & Corporate Communications

Telephone:

+45 4460 8214 or
+45 2148 0118

+45 4460 8212 or
+45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.